Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
6.62 DKK +1.85% Intraday chart for Cessatech A/S +5.08% -8.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001 CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21% MT
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Cessatech A/S Secures DKK 5 Million Loan Facility Agreement to Support the US Launch of its Lead Program CT001 CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001 CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Cessatech A/S Appoints Martin Olin as the Chairman of the Board CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Cessatech A/S Auditor Raises 'Going Concern' Doubt CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Cessatech to Raise $2 Million in Rights Offer MT
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Cessatech A/S Announces Board Changes CI
Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001 CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 CI
Chart Cessatech A/S
More charts
  1. Stock Market
  2. Equities
  3. CESSA Stock
  4. News Cessatech A/S
  5. Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%